Tech Company Financing Transactions
Lycia Therapeutics Funding Round
On 6/25/2026, Lycia Therapeutics landed $75 million in Series D funding from Balyasny Asset Management, Janus Henderson Investors and Adage Capital Management.
Transaction Overview
Company Name
Announced On
6/25/2026
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds will be used to support the clinical development of Lycia's programs, LCA-0061, a cataLYTAC� degrader designed to deplete immunoglobulin E (IgE) for food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete thyroid-stimulating hormone receptor autoantibodies (TRAbs) for Graves' disease, and to advance the company's broader pipeline of cataLYTAC degraders toward the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6175 Nancy Ridge Dr.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Lycia Therapeutics, Inc. is a biotechnology company using its lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Aetna Trombley
Founder
Carolyn Bertozzi
Browse more venture capital transactions:
Prev: 6/25/2026: Ornn AI venture capital transaction
Next: 6/25/2026: Trase AI venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs